Please assess the completion status of the following clinical trial:

Trial Title: Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 20 years of age~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks~* Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks~* Progressive castration resistant metastatic disease~* Castrate level of testosterone (\<50 ng/dL), treatment to maintain castrate levels of testosterone must be continued~Exclusion Criteria:~* Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration.~* Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy~* Has received prior hemibody external radiotherapy~* Has a need for immediate external radiotherapy~* Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug~* When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride [50 kBq/kg] (Type: EXPERIMENTAL): None
- Radium-223 dichloride [100 kBq/kg] (Type: EXPERIMENTAL): None
- Radium-223 dichloride [expansion] (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).